Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
Vaccines and Related Biological Products Advisory Committee reviewed data from the biologics license application for RBX2660 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment Recurrent C. difficile infection represents a significant burden for patients, caregivers, and the healthcare system SAINT-PREX, Switzerland & … [Read more…]
